peripheral arterial disease study
Protocol: STUDY00003967
Full Title
Validation of Plateletcrit as a marker of platelet reactivity and its effect on outcomes of lower extremity endovascular interventions
This study enrolls adults with peripheral arterial disease (PAD; blocked arteries in the legs) who are having a lower extremity endovascular intervention (EVI). The purpose of the study is to learn how well a blood test called Plateletcrit find blood clotting cells. We want to see if this test might be useful to learn about outcomes for this surgery.

You will be in this study for about 15 months. You will give 3 blood samples in addition to routine blood testing. The remainder of your care
will remain unchanged. You will come for follow up visits as determined by your vascular surgeon. Your surgeon will perform a complete history and physical and may order pictures using ultrasound to evaluate blood flow to your legs. Study takes place at Erie County Medical Center (ECMC), Buffalo General
Medical Center (BGMC) and Gates Vascular Institute (GVI).
Compensation: Yes
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Adults ages 18+
Have undergone extremity endovascular intervention (EVI) treatment of lower extremity peripheral arterial disease (PAD) or critical limb ischemia
On aspirin at time of the intervention and will receive dual antiplatelet therapy after surgery with aspirin and clopidogrel for at least 30 days.
Age Group: Adults
Principal Investigator: SIKANDAR KHAN
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email and someone will assist you.

Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact